Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALD518 intravenous infusions in rheumatoid arthritis patients with inadequate response to methotrexate
2008-004931-39Phase 2Completed
- Sponsor
- Alder Biopharmaceuticals
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of clazakizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Alder Biopharmaceuticals. Primary endpoint: Safety changes. Started Nov 2008; status: completed.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-004931-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004931-39.